Clinical Trials
12 trialsNCT03011814 2025-09-18
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT03409432 2025-07-25
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT01919619 2024-12-03
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02341014 2024-04-04
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT02561273 2023-12-13
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
University of Nebraska
Phase 1/2 Completed
NCT01553786 2021-07-26
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)
The Lymphoma Academic Research Organisation
Phase 2 Completed
NCT01742793 2020-03-04
RID
Yale University
Phase 1 Terminated
NCT00655668 2019-11-25
EXPECT
Celgene
Phase 2 Terminated
NCT01076543 2019-10-16
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01254578 2017-09-25
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
National Cancer Institute (NCI)
Phase 1 Completed
NCT00322985 2016-03-16
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma
AHS Cancer Control Alberta
Phase 2 Completed
NCT00704691 2012-04-20
Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas
University of Alabama at Birmingham
Phase EARLY_PHASE1 Terminated